Daclizumab HYP improves cognition - report
Posted: Wed Apr 20, 2016 2:23 am
Patients with relapsing-remitting multiple sclerosis (MS) treated with daclizumab high-yield process (HYP) had improved cognitive outcomes at 96 weeks compared with beta interferon, a study presented at the 68th American Academy of Neurology meeting has found...Read more - http://www.ms-uk.org/MSnews